Mito Biopharma has a strong focus on liver-based diseases which continue to represent a high unmet need. Our liver-based disease focus is further oriented by the association of mitochondrial based mechanism which relate directly to the impact of our platform technology e.g.mitochondrial modulation and uncoupling (see Our Technology). Given this synergy, our strategic focus targets the treatment of NASH e.g. Non-alcoholic steatohepatitis and type 2 diabetes, both diseases who have a clear basis in hepatic accumulation of fat, which plays a causal role in type 2 diabetes and NASH development and progression. In addition, as a secondary priority, we are also considering liver-based orphan diseases related to metabolic imbalance and metabolic defect in liver.
Although NASH has been described over 35 years ago, it was only recent that the potential of viable treatments emerged. Yet the hurdle of impacting on liver fibrosis remains elusive despite many companies entering this therapeutic space. Mito Biopharma’s ability to compete in this challenging therapeutic area relates to our differentiating and patent-protected technology impacting lipid accumulation of liver cells as well as activation of hepatic stellate cells, which are critical causative factors of NASH.